2,5-Dimethoxy-4-Methylamphetamine
"2,5-Dimethoxy-4-Methylamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Below are MeSH descriptors whose meaning is more general than "2,5-Dimethoxy-4-Methylamphetamine".
Below are MeSH descriptors whose meaning is more specific than "2,5-Dimethoxy-4-Methylamphetamine".
This graph shows the total number of publications written about "2,5-Dimethoxy-4-Methylamphetamine" by people in Harvard Catalyst Profiles by year, and whether "2,5-Dimethoxy-4-Methylamphetamine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
Below are the most recent publications written about "2,5-Dimethoxy-4-Methylamphetamine" by people in Profiles.
-
Prolonged Psychosis With Catatonia due to 2,5-Dimethoxy-4-Bromoamphetamine: Case Report and Literature Review. Psychosomatics. 2019 Nov - Dec; 60(6):599-602.
-
Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist. Neuropsychopharmacology. 2008 Aug; 33(9):2206-16.
-
A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol. 2007 Aug; 72(2):477-84.
-
Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice. Psychopharmacology (Berl). 2005 Jun; 179(4):854-62.
-
Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res. 2004 Oct 08; 1023(1):134-40.
-
High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83.